Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

@article{Spencer2009ConsolidationTW,
  title={Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.},
  author={Andrew Spencer and H Miles Prince and Andrew W Roberts and Ian W Prosser and Kenneth F. Bradstock and Luke Coyle and Devinder S Gill and Noemi Horvath and John Reynolds and Nola Kennedy},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 11},
  pages={1788-93}
}
PURPOSE Thalidomide is effective in the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). However, the role of thalidomide in the post-autologous stem cell transplantation (ASCT) context remains unclear. This study assessed whether the addition of thalidomide consolidation following ASCT would improve the durability of responses achieved and overall survival. PATIENTS AND METHODS Between January 2002 and March 2005, 269 patients with newly diagnosed MM who achieved… CONTINUE READING